Manage wisely: poly (ADP-ribose) polymerase inhibitor (PARPi) treatment and adverse events

Ainhoa Madariaga, Valerie Bowering, Soha Ahrari, Amit M Oza, Stephanie Lheureux

PARPi have transformed the Treatment Landscape of Ovarian Cancer
Several options in 1st & Recurrent setting

PARPi Adverse Events
Class Effect
Fatigue, Hematologic, Nausea
Drug Specific

Appropriate Management
✓ Safety
✓ Patient well-being
✓ Adequate dose-intensity

Selection of Maintenance PARPi
OS
PFS, PFS2
TFST, TSST

Efficacy
Target Population
Regulatory Approval
Toxicity
Quality of Life
Cost-Effectiveness/Cost-Utility
QALY ICER, Willingness to pay

Histology
BRCA, HRD
CA125 level
Residual disease
Prior treatment
Patient baseline characteristics
Clinician experience

Full Article Available at:
http://dx.doi.org/10.1136/ijgc-2020-001288